This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Endo Pharmaceuticals Holdings' CEO Discusses Q1 2012 Results - Earnings Call Transcript

Endo Pharmaceuticals Holdings Inc. (ENDP)

Q1 2012 Earnings Call

May 1, 2012 9:00 AM ET


Blaine Davis – Head, IR

David Holveck – President and CEO

Julie McHugh – EVP and COO

Alan Levin – EVP and CFO

Ivan Gergel – EVP, Research and Development


Marc Goodman – UBS

John Boris – Citi

Gregg Gilbert – Bank of America/Merrill Lynch

Ken Cacciatore – Cowen & Company

Corey Davis – Jefferies

Traver Davis – Piper Jaffray

Annabel Samimy – Stifel Nicolaus

Gary Nachman – Susquehanna

Michael Faerm – Credit Suisse

Greg Waterman – Goldman Sachs

David Buck – Buckingham Research

Jimmy Stuttman – JP Morgan

Michael Schmidt – Leerink

Irina Rivkind – Cantor Fitzgerald



Good day, ladies and gentlemen, and welcome to the Q1 2012 Endo Pharmaceuticals Earnings Conference Call.

(Operator Instructions)

I’d now like to turn the call over to Mr. Blaine Davis, Senior Vice President of Corporate Affairs. Please go ahead sir.

Blaine Davis

Good morning everyone. Thanks for joining us. With me on this morning’s call are Dave Holveck, President and CEO; Julie McHugh, Chief Operating Officer; Dr. Ivan Gergel, Chief Scientific Officer; and Alan Levin, Chief Financial Officer. After our prepared remarks, we’ll open the call to your questions.

I’d like to remind you that any forward-looking statements by management are covered under the Private Securities Litigation Reform Act of 1995 and subject to risks, change and uncertainties described in today’s press release and in our filings with the SEC.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs